Title	Antiangiogenic Agents in Cancer Therapy [electronic resource] / edited by Beverly A. Teicher
Imprint	Totowa, NJ : Humana Press : Imprint: Humana Press, 1999
Connect to	http://dx.doi.org/10.1007/978-1-59259-453-5
Descript	XI, 450 p. 37 illus., 1 illus. in color. online resource

In Antiangiogenic Agents in Cancer Therapy, Beverly Teicher and a panel of distinguished investigators survey the state-of-the-art of antiangiogenesis research from the lab bench to clinical trials. Timely and authoritative, the contributors summarize our current understanding of tumor growth and its dependence on vascular development, as well as the present status of antiangiogenic agents in preclinical and clinical development. In addition, the book also examines what is known about the mechanisms by which these therapeutic agents interfere with tumor vasculature and grapples with the problem of establishing criteria by which to assess their clinical efficacy. Antiangiogenic Agents in Cancer Therapy offers a unique cutting-edge compendium of antiangiogenic research, taking stock of what has been accomplished, where the experimental therapeutics of antiangiogenic agents are going, and the continuing evolution of their role in cancer treatment and novel drug development. Comprehensive and up-to-date, this book constitutes a key resource-rich in novel means and methods-for the clinical development of this important, highly promising new class of anticancer drugs

I. Antiangiogenic Factors and Tumor Vasculature -- 1 Angiogenesis and Blood Flow in the Solid Tumors -- 2 Oxygenation of Solid Tumors in Animals and Patients -- 3 Role of Inflammatory Mediators in Angiogenesis -- 4 Intra- and Extracellular pH in Solid Tumors -- 5 Contribution of the Extracellular Matrix and Macrophages in Angiogenesis -- 6 Regulation of Angiogenesis by the Organ Microenvironment -- 7 Fibroblast Growth Factors in Tumor Progression and Angiogenesis -- 8 Role of Vascular Endothelial Growth Factor in Regulation of Angiogenesis -- 9 Regulatory Aspects of Neovascularization: Regulation of Wound Angiogenesis by Metabolic Alterations -- II. Antiangiogenic Agents -- 10 Squalamine: A New Angiostatic Steroid -- 11 Cartilage as a Source of Natural Inhibitors of Angiogenesis -- 12 Thrombospondin as an Inhibitor of Angiogenesis -- 13 Matrix Metalloproteinase Inhibitors -- 14 Angiostatin and Other Plasminogen Fragments -- 15 Dietary and Nutritional Modulation of Tumor Angiogenesis -- 16 Thalidomide and Analogs -- III. In Vivo Studies and Clinical Trials -- 17 Potentiation of Cytotoxic Cancer Therapies by Antiangiogenic Agents -- 18 Prognostic Significance of Tumor Vascularity -- 19 Endpoints for Determination of Efficacy of Antiangiogenic Agents in Clinical Trials -- 20 Retinoids and Interferons as Antiangiogenic Cancer Drugs -- 21 Pentosan Polysulfate: A Polysaccharide That Inhibits Angiogenesis by Binding Growth Factors -- 22 TNP-470 -- 23 Batmastat and Marmastat in Cancer: Summary of Early Clinical Data -- 24 Thalidomide: A Prodrug That Inhibits Angiogenesis -- 25 Ribozyme Targeting of Angiogenic Molecules